Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $109.62M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 0.86M
Average 0.66M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +33.0% | +76.3% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +33.0% over three years. Forward estimates point to Revenue at +76.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Spyre Therapeutics, Inc. NASDAQ:SYRE | $9.88B | $104.00 | Not rated | -171.1 | +315.98% |
Relay Therapeutics, Inc. NASDAQ:RLAY | $4.00B | $18.09 | Not rated | -10.5 | +149.37% |
Amylyx Pharmaceuticals, Inc. NASDAQ:AMLX | $3.89B | $30.29 | Not rated | -11.3 | +93.07% |
Pharvaris N.V. NASDAQ:PHVS | $2.34B | $33.36 | Not rated | -11.0 | +30.83% |
Zenas BioPharma, Inc. NASDAQ:ZBIO | $1.90B | $28.01 | Not rated | -2.5 | -28.13% |
Novavax, Inc. NASDAQ:NVAX | $1.41B | $8.53 | Not rated | -17.3 | +24.12% |
Intellia Therapeutics, Inc. NASDAQ:NTLA | $1.36B | $9.70 | Not rated | -4.6 | +18.41% |
Syndax Pharmaceuticals, Inc. NASDAQ:SNDX | $850.77M | $9.45 | Not rated | -6.8 | -46.45% |
Wave Life Sciences Ltd. NASDAQ:WVE | $617.33M | $3.13 | Not rated | -6.6 | -59.76% |
Continue the stock analysis
Jump to another research area for this company.